Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Core Insights - Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform [3] Group 1: Company Overview - Benitec is headquartered in Hayward, California and specializes in gene therapy aimed at chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [3] - The "Silence and Replace" platform combines RNA interference with gene therapy to enable sustained silencing of disease-causing genes while delivering wildtype replacement genes in a single administration [3] Group 2: Upcoming Events - CEO Jerel A. Banks will participate in the Guggenheim Securities Healthcare Conference in Boston from November 11-13, 2024 [1] - The presentation will include a fireside chat and one-on-one meetings, with a live webcast available for interested parties [2]